Haritha Laboratories Profile
Key Indicators
- Authorised Capital ₹ 4.70 M
as on 25-07-2024
- Paid Up Capital ₹ 4.70 M
as on 25-07-2024
- Company Age 16 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.40 M
as on 25-07-2024
- Satisfied Charges ₹ 4.80 M
as on 25-07-2024
- Revenue -31.48%
(FY 2023)
- Profit -46.94%
(FY 2023)
- Ebitda -46.15%
(FY 2023)
- Net Worth -0.76%
(FY 2023)
- Total Assets -0.57%
(FY 2023)
About Haritha Laboratories
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.70 M and a paid-up capital of Rs 4.70 M.
The company currently has active open charges totaling ₹9.40 M. The company has closed loans amounting to ₹4.80 M, as per Ministry of Corporate Affairs (MCA) records.
Narendra Kantipudi and Gurram Subbalakshmi serve as directors at the Company.
- CIN/LLPIN
U74900TG2008PTC061558
- Company No.
061558
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Oct 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Patancheru Mandal, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Haritha Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narendra Kantipudi  | Director | 08-Dec-2022 | Current |
| Gurram Subbalakshmi | Director | 20-Apr-2016 | Current |
Financial Performance and Corporate Structure Insights of Haritha Laboratories.
Haritha Laboratories Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 31.48% decrease. The company also saw a substantial fall in profitability, with a 46.94% decrease in profit. The company's net worth dipped by a decrease of 0.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Haritha Laboratories?
In 2023, Haritha Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Slb Pharma Private LimitedActive 17 years 9 monthsNarendra Kantipudi and Gurram Subbalakshmi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 05 Dec 2012 | ₹9.40 M | Open |
Bank Of India Creation Date: 12 Aug 2009 | ₹4.80 M | Satisfied |
How Many Employees Work at Haritha Laboratories?
Unlock and access historical data on people associated with Haritha Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Haritha Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Haritha Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
